3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Hodgkin Disease
36
Lymphoma
34
Lymphoma, Non-Hodgkin
24
Lymphoma, Large B-Cell, Diffuse
24
Lymphoma, Follicular
18
Lymphoma, B-Cell
16
Recurrence
15
Melanoma
14
Neoplasms
12
Mycosis Fungoides
9
Lymphoma, T-Cell
9
Breast Neoplasms
9
Leukemia, Lymphocytic, Chronic, B-Cell
8
Carcinoma, Non-Small-Cell Lung
8
Squamous Cell Carcinoma of Head and Neck
7
Lymphoma, T-Cell, Cutaneous
7
Lymphoma, B-Cell, Marginal Zone
7
Head and Neck Neoplasms
7
Sezary Syndrome
6
Pancreatic Neoplasms
6
Ovarian Neoplasms
6
Lymphoma, Mantle-Cell
6
Lung Neoplasms
6
Carcinoma, Renal Cell
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Neoplasm Metastasis
5
Lymphoma, T-Cell, Peripheral
5
Waldenstrom Macroglobulinemia
4
Uterine Cervical Neoplasms
4
Urinary Bladder Neoplasms
4
Interventions
Cyclophosphamide
8
Rituximab
7
fludarabine
6
dacetuzumab
6
fludarabine phosphate
5
blinatumomab
4
Bortezomib
4
ibrutinib
3
Melphalan
3
Lenalidomide
3
Ifosfamide
3
Etoposide
3
Dexamethasone
3
Bendamustine Hydrochloride
3
AP 1903 reagent
3
ponatinib
2
cobomarsen
2
Whole-Body Irradiation
2
Vorinostat
2
Vincristine
2
Tacrolimus
2
Prednisone
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Mesna
2
Doxorubicin
2
Carboplatin
2
Busulfan
2
Brentuximab Vedotin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Immunoproliferative Disorders
×
pembrolizumab
×
Lymphoid
×
Clear all
NCT03349450
2026-05-06
SPiReL
Sunnybrook Health Sciences Centre
Phase 2
Completed
25 enrolled
18 charts